Developer docs
API playgroundTry for free, no card

Search company profiles

Intarcia Therapeutics

Full company profile

uuid0000rer

Namestring
Intarcia Therapeutics
Websiteurl
intarcia.com
Company typeenum
Private
Founded yearint
1997
Descriptiontext

Intarcia Therapeutics is a privately held, clinical-stage biopharmaceutical company founded in 1997 and headquartered in Hayward, California, that develops therapies for diseases requiring long-term chronic treatment. The firm has built a 251-500 employee organization and has financed its operations through 20+ disclosed funding rounds since 2000, accumulating in excess of $1.7 billion from a syndicate of healthcare-focused institutional investors including NEA, Venrock, RA Capital Management, Baillie Gifford, Fidelity, Foresite Capital, and the Bill & Melinda Gates Foundation. Leadership indicates a regulated pharmaceutical operating model, with dedicated roles for Global Regulatory Affairs and Quality, Regulatory Compliance, Chemistry, and a Chief Medical Officer who also heads Regulatory Affairs globally.

The business model is a pre-commercial therapeutics developer, with all disclosed financial metrics showing operating losses and no product revenue line. Revenue mechanics, pricing, distribution channels, and customer segments are not disclosed in the provided sources, and the company's own domain (intarcia.com) is currently listed for sale on the Atom marketplace rather than pointing to an active corporate site, which together with the absence of any disclosed post-2019 funding or product milestones limits visibility on current operating status. The single disclosed corporate transaction in the record is the September 2015 acquisition of Phoundry Pharmaceuticals for an undisclosed amount, used to expand the development pipeline.

Short descriptiontext

Intarcia Therapeutics is a Hayward, California-based, privately held biopharmaceutical company founded in 1997 that develops therapies for chronic, long-term diseases, funded by 20+ rounds totaling over $1.7 billion from healthcare-focused institutional investors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
chronic disease therapy, implantable drug delivery, long-acting therapeutics, pharmaceutical development, type 2 diabetes treatment
Industry2 codes
PRIMARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
SECONDARYHLAHAHAJ
Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
NAICS code1 code
  • Other Ambulatory Health Care Services6219
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Surgical & Medical Instruments & Apparatus3841
Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment, centered on a proprietary long-acting implantable drug delivery system designed to provide continuous, steady-state dosing of medication over extended periods (months to a year or more) for patients with chronic conditions such as type 2 diabetes. The company combines drug formulation science with a miniaturized subcutaneous delivery device to reduce dosing frequency and improve adherence in chronic disease management.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

No product or service information for Intarcia Therapeutics was found in the provided source data. The available sources contained only a domain marketplace listing for the sale of the intarcia.com domain name, and an unrelated market report about refrigerator display cases in Spain.

Product and service1 record
1Long-acting implantable therapy for chronic diseases
CategoryPharmaceutical / drug-device combination therapy
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Acquired Amylin and markets Bydureon BCise (exenatide once-weekly). Directly relevant incumbent in the same molecule and indication Intarcia targeted.

TypeEmerging player
Description

Developed inhaled insulin (Dance 501) using a proprietary delivery platform. Comparable niche chronic-disease device-pharma hybrid targeting type 2 diabetes.

TypeBroad incumbent
Description

Omnipod tubeless insulin pump for diabetes. Comparable as a durable device-based diabetes therapy platform serving the same end-prescribers and patients.

4Amylin Pharmaceuticals
TypeDirect peer
Description

Developed sustained-release exenatide (Bydureon), the same GLP-1 molecule Intarcia's ITCA 650 sought to deliver via an implantable pump. Acquired by AstraZeneca in 2012; directly comparable molecule, indication, and delivery-format ambitions.

TypeDirect peer
Description

Developer of Afrezza (inhaled insulin) and the Technosphere drug-delivery platform. Closest pure-play peer in chronic-disease drug delivery technology with a proprietary device-based platform.

TypeDirect peer
Description

Developed V-Go, a wearable basal insulin delivery device for type 2 diabetes. Comparable in targeting adherence challenges in type 2 diabetes via an alternative delivery format.

TypeBroad incumbent
Description

Global GLP-1 leader (Ozempic, Rybelsus, Victoza) for type 2 diabetes and obesity. Sets the competitive standard Intarcia's long-acting delivery would need to displace.

TypeBroad incumbent
Description

Major diabetes franchise (Trulicity, Mounjaro, Zepbound) and broad metabolic-disease pipeline. Defines the GLP-1 competitive landscape Intarcia would need to penetrate.

TypeBroad incumbent
Description

Leading continuous glucose monitoring (CGM) franchise. Adjacent but relevant — defines the connected diabetes device ecosystem into which Intarcia's delivery platform would integrate.

TypeEmerging player
Description

Insulin pump and connected diabetes management devices (t:slim, t:slim X2). Comparable as an innovative device-led diabetes therapy company targeting improved adherence and outcomes.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses2 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds22 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors28 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Intarcia Therapeutics

Intarcia Therapeutics is a Hayward, California-based, privately held biopharmaceutical company founded in 1997 that develops therapies for chronic, long-term diseases, funded by 20+ rounds totaling over $1.7 billion from healthcare-focused institutional investors.

What Intarcia Therapeutics does

Intarcia Therapeutics is a privately held, clinical-stage biopharmaceutical company founded in 1997 and headquartered in Hayward, California, that develops therapies for diseases requiring long-term chronic treatment. The firm has built a 251-500 employee organization and has financed its operations through 20+ disclosed funding rounds since 2000, accumulating in excess of $1.7 billion from a syndicate of healthcare-focused institutional investors including NEA, Venrock, RA Capital Management, Baillie Gifford, Fidelity, Foresite Capital, and the Bill & Melinda Gates Foundation. Leadership indicates a regulated pharmaceutical operating model, with dedicated roles for Global Regulatory Affairs and Quality, Regulatory Compliance, Chemistry, and a Chief Medical Officer who also heads Regulatory Affairs globally.

The business model is a pre-commercial therapeutics developer, with all disclosed financial metrics showing operating losses and no product revenue line. Revenue mechanics, pricing, distribution channels, and customer segments are not disclosed in the provided sources, and the company's own domain (intarcia.com) is currently listed for sale on the Atom marketplace rather than pointing to an active corporate site, which together with the absence of any disclosed post-2019 funding or product milestones limits visibility on current operating status. The single disclosed corporate transaction in the record is the September 2015 acquisition of Phoundry Pharmaceuticals for an undisclosed amount, used to expand the development pipeline.

Intarcia Therapeutics firmographics

Firmographics
Name
Intarcia Therapeutics
Website
https://intarcia.com
Company type
Private
Founded year
1997
Operating status
Operating
Headcount range
51–100 employees
Short description
Intarcia Therapeutics is a Hayward, California-based, privately held biopharmaceutical company founded in 1997 that develops therapies for chronic, long-term diseases, funded by 20+ rounds totaling over $1.7 billion from healthcare-focused institutional investors.
Ownership category
akta.pro rank

Intarcia Therapeutics industry classification

Industry
NAICS
Other Ambulatory Health Care Services (6219)
SIC
Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
SECONDARYHLAHAHAJ
Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)

Keywords

  • Chronic disease therapy
  • Implantable drug delivery
  • Long-acting therapeutics
  • Pharmaceutical development
  • Type 2 diabetes treatment

Where Intarcia Therapeutics is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Markets served

Intarcia Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Intarcia Therapeutics product offering

Product offering

Core offering

Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment, centered on a proprietary long-acting implantable drug delivery system designed to provide continuous, steady-state dosing of medication over extended periods (months to a year or more) for patients with chronic conditions such as type 2 diabetes. The company combines drug formulation science with a miniaturized subcutaneous delivery device to reduce dosing frequency and improve adherence in chronic disease management.

Product overview

No product or service information for Intarcia Therapeutics was found in the provided source data. The available sources contained only a domain marketplace listing for the sale of the intarcia.com domain name, and an unrelated market report about refrigerator display cases in Spain.

Differentiator

Problem solved

Functional benefit

Products and services

  • Long-acting implantable therapy for chronic diseases

Companies that use Intarcia Therapeutics

Customer profile

Ideal customer profiles1 record

Intarcia Therapeutics technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Intarcia Therapeutics partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights4 records

Intarcia Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • AstraZeneca: Acquired Amylin and markets Bydureon BCise (exenatide once-weekly). Directly relevant incumbent in the same molecule and indication Intarcia targeted.
  • Insulet Corporation: Omnipod tubeless insulin pump for diabetes. Comparable as a durable device-based diabetes therapy platform serving the same end-prescribers and patients.
  • Novo Nordisk: Global GLP-1 leader (Ozempic, Rybelsus, Victoza) for type 2 diabetes and obesity. Sets the competitive standard Intarcia's long-acting delivery would need to displace.
  • Eli Lilly: Major diabetes franchise (Trulicity, Mounjaro, Zepbound) and broad metabolic-disease pipeline. Defines the GLP-1 competitive landscape Intarcia would need to penetrate.
  • Dexcom: Leading continuous glucose monitoring (CGM) franchise. Adjacent but relevant — defines the connected diabetes device ecosystem into which Intarcia's delivery platform would integrate.

Emerging players

  • Dance Biopharm: Developed inhaled insulin (Dance 501) using a proprietary delivery platform. Comparable niche chronic-disease device-pharma hybrid targeting type 2 diabetes.
  • Tandem Diabetes Care: Insulin pump and connected diabetes management devices (t:slim, t:slim X2). Comparable as an innovative device-led diabetes therapy company targeting improved adherence and outcomes.

Direct peers

  • Amylin Pharmaceuticals: Developed sustained-release exenatide (Bydureon), the same GLP-1 molecule Intarcia's ITCA 650 sought to deliver via an implantable pump. Acquired by AstraZeneca in 2012; directly comparable molecule, indication, and delivery-format ambitions.
  • MannKind Corporation: Developer of Afrezza (inhaled insulin) and the Technosphere drug-delivery platform. Closest pure-play peer in chronic-disease drug delivery technology with a proprietary device-based platform.
  • Valeritas: Developed V-Go, a wearable basal insulin delivery device for type 2 diabetes. Comparable in targeting adherence challenges in type 2 diabetes via an alternative delivery format.

Market position

Strengths4 records

Weaknesses2 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

Intarcia Therapeutics social profiles

Digital presence

Intarcia Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Intarcia Therapeutics leadership team

Management profile

Number of profiles

Profiles7 records

Intarcia Therapeutics funding detail

Funding detail

Funding overview

Funding rounds22 records

Investors28 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Intarcia Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Intarcia Therapeutics

What does Intarcia Therapeutics do?

Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment, centered on a proprietary long-acting implantable drug delivery system designed to provide continuous, steady-state dosing of medication over extended periods (months to a year or more) for patients with chronic conditions such as type 2 diabetes. The company combines drug formulation science with a miniaturized subcutaneous delivery device to reduce dosing frequency and improve adherence in chronic disease management.

Is Intarcia Therapeutics a public or private company?

Intarcia Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Intarcia Therapeutics founded?

Intarcia Therapeutics was founded in 1997. It employs 51 to 100 people.

Where is Intarcia Therapeutics based?

Intarcia Therapeutics is headquartered in Boston, United States, in the North America region.

Who are Intarcia Therapeutics's main competitors?

Broad incumbents on record are AstraZeneca, Insulet Corporation, Novo Nordisk, Eli Lilly and Dexcom. Emerging players are Dance Biopharm and Tandem Diabetes Care. Direct peers are Amylin Pharmaceuticals, MannKind Corporation and Valeritas.

Does Intarcia Therapeutics have an API?

No public API is recorded for Intarcia Therapeutics.

What industry is Intarcia Therapeutics in?

Its primary akta.pro industry code is HLAIACAE, Gastroenterology Specialty Pharmaceuticals, with a secondary code of HLAHAHAJ, Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators). Its NAICS code is 6219 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
STATFDA panel votes against GLP-1 therapy from former diabetes unicorn IntarciaAn FDA advisory panel unanimously voted against Intarcia Therapeutics' implantable diabetes device, which delivers exenatide continuously over six months. The panel was convened after the FDA rejected the device twice. The agency is not bound to follow the panel's advice.BioPharma DiveIntarcia, a former biotech unicorn, gets new life with startup deali2o Therapeutics has acquired the assets of former biotech unicorn Intarcia Therapeutics, including its diabetes drug-eluting implant ITCA 650 and the underlying Medici delivery technology. The Boston-based startup secured a $46 million Series A round and appointed Intarcia's former CEO Kurt Graves as its chairman and CEO to advance the drug toward FDA approval. This acquisition positions i2o to re-argue its case before an FDA advisory committee scheduled for September 21 regarding safety concerns previously raised by regulators.WsjIntarcia Therapeutics Takes One Last Shot at FDA ApprovalIntarcia Therapeutics is appealing two FDA rejections of its Type 2 diabetes treatment ITCA 650. The company, once valued at $4.2 billion with over 300 employees, aims to deliver exenatide via a matchstick-sized implant to avoid daily or weekly injections.STATAfter repeated FDA rejections, key investor writes down stake in former diabetes unicorn Intarcia TherapeuticsLuxin Venture Capital Group wrote down its $30 million investment in Intarcia Therapeutics to zero after the FDA rejected the company's diabetes implant twice. Intarcia is appealing the rejections, but the write-down signals investor loss of confidence.PR NewswireIntarcia Therapeutics Provides Regulatory Update - FDA Accepts Resubmitted New Drug Application For ITCA 650Intarcia Therapeutics announced that the FDA has accepted the company's resubmission of its new drug application for ITCA 650, an exenatide implant for treating type 2 diabetes. The FDA has designated the resubmission as a complete class 2 response with a Prescription Drug User Fee Act (PDUFA) target action date of March 9, 2020. If approved, ITCA 650 would represent the first twice-yearly GLP-1 receptor agonist delivery system for maintenance therapy of type 2 diabetes.FierceBiotechIntarcia vs. Novo: Which has the most appealing diabetes PhIII program?Intarcia's implanted extended-release drug ITCA-650 outperformed Merck's Januvia in a recent study, prompting analysts to compare it with Novo Nordisk's Phase IIIa oral semaglutide program. Both could compete in the GLP-1 class, with Intarcia likely to file in the first half of 2016.PR NewswireIntarcia Provides 2019 Corporate UpdateIntarcia Therapeutics Inc. announced a 2019 corporate update highlighting the appointment of three new senior leaders in 2018: Dr. Fred Fiedorek as Chief Medical Officer, Anders Vinther as Global Head of Quality & Engagement, and Thane Wettig as Chief Marketing Officer. The company reported significant progress toward resubmitting its New Drug Application for ITCA 650, its lead investigational therapy for type 2 diabetes, with the FDA submission expected in mid-2019 after consultations to address deficiencies from a prior complete response letter. The leadership team emphasized their focus on advancing the GLP-1 class development and preparing for commercial launch of this chronic therapy delivery platform.PR NewswireIntarcia Appoints Thane Wettig as Chief Marketing Officer and Metabolic Franchise HeadIntarcia Therapeutics Inc. announced the appointment of Thane Wettig as Chief Marketing Officer and Metabolic Franchise Head, a newly created role reporting directly to CEO Kurt Graves. Wettig previously served as CMO for Lilly Diabetes at Eli Lilly & Co., where he led a team responsible for blockbuster diabetes brands including Humalog, Byetta, Jardiance, Trulicity, and Basaglar. In his new role, Wettig will lead Intarcia's marketing team and drive the launch plan for ITCA 650, the company's investigational therapy for type 2 diabetes.BostonGlobe.comFDA balks at Intarcia’s diabetes drug pumpThe FDA rejected Intarcia Therapeutics' diabetes drug pump, citing questions about manufacturing practices. The Boston biotech plans to address concerns but expects no additional testing. CEO Kurt Graves said the company remains confident in the device's approvability.AxiosFDA slows down diabetes "unicorn"The FDA sent a Complete Response Letter to Intarcia Therapeutics, delaying U.S. commercialization of its Type II diabetes implant from Q4 2017 to H2 2018. The company says no additional clinical trials are needed. CEO Kurt Graves said the company will still commercialize before IPO.